Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Harjot Singh Vohra
Observed name:
Harjot Vohra
Institution:
Princess Margaret Cancer Centre
Observed institution:
Princess Margaret Cancer Centre
ORCID:
0009-0009-0246-7468
Observed ORCID:
0009-0009-0246-7468
OpenAlex ID:
A5033716003
Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
2014
·
Craig B. Reeder
, Donna E. Reece
, et al.
·
British Journal of Haematology
·
42
PDF
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025
·
Tess Aalto
, Maria Abacan
, et al.
·
Cancer Cell
·
5
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment
2026
·
Rintu Sharma
, Eshetu G. Atenafu
, et al.
·
European Journal Of Haematology
·
2
PDF
Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases
2025
·
Rintu Sharma
, Alfredo de la Torre
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
2
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
·
Blood Cancer Discovery
·
1
PDF
Debulking Chemotherapy Abrogates the Risk of Non-Response in Multiple Myeloma Patients with High Tumor Burden Receiving Teclistamab
2025
·
Rintu Sharma
, Esther Masih-Khan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
2024
·
Anup Joseph Devasia
, Olsen Chan
, et al.
·
Blood
·
1
PDF
Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
2024
·
Rintu Sharma
, Pamella Paul
, et al.
·
Blood
·
1
Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
2023
·
Anup J Devasia
, Sahar Khan
, et al.
·
Blood
·
1
PDF
PA-373 Prospective Study of Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EasyM) in patients with Newly Diagnosed Multiple Myeloma (NDMM)
2026
·
Rintu Sharma
, Esther Masih-Khan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Supplementary Figure 3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
Supplementary Figure 1 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
Data from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
Supplementary Tables S1-S3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
Supplementary Figure 2 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
2026
·
Rintu Sharma
, Andree-Anne Pelland
, et al.
Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)
2025
·
Rintu Sharma
, Esther Masih-Khan
, et al.
·
Blood
Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?
2025
·
Steven Chun-Min Shih
, Harjot Singh Vohra
, et al.
·
Blood
PDF
Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy
2025
·
Rintu Sharma
, Pamella Paul
, et al.
·
Blood
PDF
Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EASYM) in patients with Newly Diagnosed Multiple Myeloma
2025
·
Rintu Sharma
, Esther Masih-Khan
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Operationalising Patient Selection for Outpatient Transplant in Multiple Myeloma: Subjective Versus Objective Measures
2025
·
Steven Chun-Min Shih
, Harjot Vohra
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Longitudinal Analysis of Clonal Hematopoietic Mutations (CHIP) in Transplant Eligible Multiple Myeloma (MM) Patients: Trends From Pre-Transplant to 1 Year
2025
·
Sahar Khan
, Salman Basrai
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Desensitization of Immunomodulating Agent–Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
2025
·
Jack T. Seki
, Eshetu G. Atenafu
, et al.
·
Journal of Clinical Pharmacy and Therapeutics
PDF
Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
2024
·
Steven Shih
, Harjot Vohra
, et al.
·
Blood
PDF
Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
2024
·
Sahar Khan
, Salman Basrai
, et al.
·
Blood
PDF
Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden
2024
·
Rintu Sharma
, Karla Alexandra Sanchez
, et al.
·
Blood
Show more works
View as search
Works count:
27
Citation count:
56
H-index:
2
I10-index:
1
Year
Topic
Type
